The Board of Directors of Presbia PLC (NASDAQ: LENS), an ophthalmic
device company and leader in near-vision restoration, announced today
that it has appointed Gerald Farrell, Ph.D. to serve on its Board of
Directors and as a member of its Audit Committee.
Dr. Farrell has been involved in the pharmaceutical industry for more
than 25 years, and worked for Eli Lilly Company Limited in Ireland and
the United Kingdom for the majority of his successful career. Dr.
Farrell's tenure at Eli Lilly included positions of Managing Director,
leading the commercial sales and marketing in Ireland where he launched
several major products in Europe; Director Strategy, Commercial and
Business in the UK accountable for long-term strategic planning and
business operations as well as other positions related to compliance,
production, sales, and planning.
"Presbia will benefit from Gerald's experience and success in
consumer-oriented healthcare, and building organizations and teams
across countries as we execute our strategic commercial roll out in both
Asia and Europe," said Randy Thurman, Executive Chairman of Presbia PLC.
"He will be joining a strong group of directors and officers leading the
company as Presbia continues to execute its goal of being the best
solution for presbyopia, an affliction that affects 1.8 billion people
Dr. Farrell earned a Ph.D. Plant Biotechnology from University College,
Cork, and a BSc Honours - Plant Science and Higher Diploma Education
with Honours from University College, Galway. Dr. Farrell serves on the
Board for UCD Michael Smurfit Graduate Business School, serves as a
director, and previously served as president, for Irish Pharmaceutical
Healthcare Association, and serves as a council member for the Dublin
Chamber of Commerce. Previously, from 2003 until 2014, Dr. Farrell
served as a director of Eli Lilly and Company (Ireland) Ltd.
This release contains "forward-looking statements" made pursuant to the
safe harbor provisions of the Private Securities Litigation Reform Act
of 1995. Information provided and statements contained in this press
release that are not purely historical are forward-looking statements.
Such forward-looking statements only speak as of the date of this press
release and Presbia assumes no obligation to update the information
included in this press release. Statements made in this press release
that are forward-looking in nature may involve risks and uncertainties,
including, but not limited to, the factors listed under "Risk Factors"
in our annual report on Form 10-K and quarterly reports on Form 10-Q.
Accordingly, readers are cautioned that any such forward-looking
statements are not guarantees and are subject to certain risks,
uncertainties and assumptions that are difficult to predict. Although
Presbia believes that the expectations reflected in such forward-looking
statements are reasonable as of the date made, expectations may prove to
have been materially different from the results expressed or implied by
such forward-looking statements. Unless otherwise required by law,
Presbia also disclaims any obligation to update its view of any such
risks or uncertainties or to announce publicly the result of any
revisions to the forward-looking statements made in this press release.
Presbia PLC (NASDAQ:LENS) is an ophthalmic device company that has
developed and is currently marketing the presbyopia-correcting Presbia
Flexivue Microlens™, a miniature lens that is implanted in a corneal
pocket created by a femtosecond laser. The Presbia Flexivue Microlens™
has received a CE mark for the European Economic Area, allowing the lens
to be marketed in over 30 countries across Europe. A staged pivotal U.S.
clinical trial for the Presbia Flexivue Microlens™ commenced in 2014.
View source version on businesswire.com: http://www.businesswire.com/news/home/20160120006403/en/
Monica Yamada, 323-860-4903
Source: Presbia PLC
News Provided by Acquire Media